The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction

Sponsor
University of Sao Paulo (Other)
Overall Status
Completed
CT.gov ID
NCT01250353
Collaborator
(none)
127
1
2
37
3.4

Study Details

Study Description

Brief Summary

The main problem of ocular surface reconstruction is the lack of viable conjunctival tissue. The use of a biocompatible latex biomembrane in ocular surface healing, like post pterygium surgery, could be an alternative therapeutic resource to this process.

Condition or Disease Intervention/Treatment Phase
  • Procedure: pterygium surgery
Phase 2

Detailed Description

The latex biomembrane is considered biocompatible and believed to promote neoformation of biological tissues. It also induces vascular neoformation and promotes extra cellular provisional matrix formation, fundamental steps for any kind of wound healing. In humans, it was successfully used in chronic cutaneous ulcer and otologic surgeries. In rabbits' eyes, the latex biomembrane was efficient in ocular surface reconstruction with adequate conjunctiva functional recovery, compared to bare sclera. To study the latex biomembrane action in human ocular surface, it was compared to conjunctival autograft in humans eyes. Considering the deficiency of adequate sized groups and the pterygium recurrences criteria differences, this study proposes the fibrovascular tissue growing measure like an auxiliary method of pos-operative evaluation. The biomembrane of natural latex seems to be efficient in ocular surface reconstruction and must be employed in future studies of other ocular pathologies. This material revealed to be a new source of therapeutic resort to external eye diseases and conjunctival replace in surgeries living bare sclera.

Study Design

Study Type:
Interventional
Actual Enrollment :
127 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction and Pterygium
Study Start Date :
Jun 1, 2006
Actual Primary Completion Date :
Jun 1, 2007
Actual Study Completion Date :
Jul 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: conjunctival autograft

The conjunctival autograft was performed after the pterygium surgery like usual technique.

Procedure: pterygium surgery
pterygium was removed surgically
Other Names:
  • pterygium excision
  • prevention of pterygium recurrence
  • Experimental: latex biomembrane application

    The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.

    Procedure: pterygium surgery
    pterygium was removed surgically
    Other Names:
  • pterygium excision
  • prevention of pterygium recurrence
  • Outcome Measures

    Primary Outcome Measures

    1. change in fibrovascular tissue growing measure [twelve months]

      The fibrovascular tissue growing measure was designed to be an auxiliary method of pos-operative evaluation. At the slit lamp, the pterygium or the fibrovascular growing tissue was measured related to anatomic limbus. To the scleral side was given negative value and to the cornea side was given positive value. The anatomic limbus was the zero in this scale. The results were compared at inicial stage and three, six and twelve months, to evaluate the progression and recurrence probability.

    Secondary Outcome Measures

    1. pterygium recurrence [twelve months]

      Pterygium recurrence was defined like fibrovascular tissue growing up to 1,5mm across the anatomic limbus.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • symptomatic pterygium
    Exclusion Criteria:
    • any other ocular surface pathology, glaucoma, retinal disease, pregnancy, auto immune disease, severe systemic disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Erika Christina Canarim Martha de Pinho Ribeirão Preto SP Brazil

    Sponsors and Collaborators

    • University of Sao Paulo

    Investigators

    • Study Chair: Sidney JF Sousa, phD, Ribeirão Preto Faculty of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01250353
    Other Study ID Numbers:
    • 12416/05
    First Posted:
    Nov 30, 2010
    Last Update Posted:
    Nov 30, 2010
    Last Verified:
    Dec 1, 2009

    Study Results

    No Results Posted as of Nov 30, 2010